Tonix Pharm Hldg (TNXP) Posts Q1 Loss of 59c/Share

Go back to Tonix Pharm Hldg (TNXP) Posts Q1 Loss of 59c/Share

Enrollment in Tonix (TNXP) BESTFIT Trial Completed

May 12, 2014 8:41 AM EDT

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that it has completed enrollment in the BESTFIT trial of TNX-102 SL for fibromyalgia, after having achieved the randomization goal of 200 subjects.

BESTFIT (BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy) is a 12-week, randomized, double-blind, placebo-controlled trial of TNX-102 SL (cyclobenzaprine... More